Medpace Holdings Inc
$ 590.67
0.97%
07 Aug - close price
- Market Cap 16,486,577,000 USD
- Current Price $ 590.67
- High / Low $ 594.99 / 582.08
- Stock P/E 34.75
- Book Value 15.54
- EPS 17.00
- Next Earning Report 2026-10-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.20 %
- ROE 1.62 %
- 52 Week High 677.90
- 52 Week Low 373.00
About
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Analyst Target Price
$581.83
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-22 | 2026-04-22 | 2026-02-09 | 2025-10-22 | 2025-07-21 | 2025-04-21 | 2025-02-10 | 2024-10-21 | 2024-07-22 | 2024-04-22 | 2024-02-12 | 2023-10-23 |
| Reported EPS | 4.25 | 4.28 | 4.67 | 3.86 | 3.1 | 3.67 | 3.6813 | 3.01 | 2.76 | 3.22 | 2.46 | 2.24 |
| Estimated EPS | 4.08 | 3.96 | 4.18 | 3.57 | 3 | 3.07 | 3.1167 | 2.87 | 2.63 | 2.49 | 2.22 | 2.19 |
| Surprise | 0.17 | 0.32 | 0.49 | 0.29 | 0.1 | 0.6 | 0.5646 | 0.14 | 0.13 | 0.73 | 0.24 | 0.05 |
| Surprise Percentage | 4.1667% | 8.0808% | 11.7225% | 8.1232% | 3.3333% | 19.544% | 18.1153% | 4.878% | 4.943% | 29.3173% | 10.8108% | 2.2831% |
Next Quarterly Earnings
| Sep 2026 | |
|---|---|
| Reported Date | 2026-10-19 |
| Fiscal Date Ending | 2026-09-30 |
| Estimated EPS | 4.44 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MEDP
2026-08-07 20:40:47
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Medpace securities before April 22, 2025, and still hold them, to contact them to assist with the investigation. This investigation aims to restore investor capital and ensure corporate accountability.
2026-08-07 18:40:46
This article reports on Medpace Holdings, Inc.'s SEC Form 144 filing on August 7, 2026, detailing a proposed sale of securities. The filing indicates the sale of 795 shares of common stock acquired through stock option exercise on the same date, with an aggregate market value of $465,131.45. The article also provides Medpace's stock data, rankings, and recent news and SEC filings.
2026-08-07 18:40:46
The article discusses whether Medpace Holdings, Inc. (NASDAQ:MEDP) is a good investment at its current share price of US$585. It delves into the company's valuation, considering factors such as its price-to-earnings (P/E) ratio and future growth prospects. The analysis aims to help potential investors determine if Medpace is trading at a fair value or if there's an opportunity for upside.
2026-08-07 17:40:47
This page provides news and analysis for Medpace Holdings Inc (MEDP). It highlights the company's stock performance, including a recent surge after strong earnings, and offers various financial and analytical tools for investors. The article mentions a significant event where Medpace's strong earnings caused its shares to surge by 54%.
2026-08-06 17:40:46
The Manufacturers Life Insurance Company reduced its stake in Medpace Holdings, Inc. ($MEDP) by 12.5% in the first quarter, selling 2,063 shares. Despite this, Medpace reported strong quarterly results with higher-than-expected EPS and revenue, and issued positive fiscal 2026 EPS guidance. The stock opened at $587.75, with analysts maintaining a "Hold" rating and an average price target of $584.18, while company insiders have recently sold shares worth $16.2 million.
2026-08-06 11:02:00
Medpace Holdings, Inc. (MEDP) exhibits compelling growth with double-digit earnings, strong profitability, and improving bookings, along with a significant pipeline for 2027. However, its valuation is considerably higher than industry and market averages. While the company's operational quality is high, the premium valuation and potential for uneven booking visibility suggest a selective approach rather than aggressive buying.
